Syndicated Research Studies

Cancer diagnosis used to hinge almost entirely on the trained eye of a radiologist or pathologist, working scan by scan, slide by slide. That model is now being layered — not replaced, but sharpened — by algorithms that can flag a suspicious lesion in milliseconds or predict a chemotherapy dose from a CT scan's fat, bone, and muscle composition. That shift is exactly what's fueling the AI in oncology market , valued at USD 6.0 billion in 2025 and on track to hit USD 38.9 billion by 2033, expanding at a CAGR of 24.8% from 2026 onward. Numbers this steep usually signal one of two things: a speculative bubble, or a genuine infrastructure shift in how an entire discipline operates. Cancer AI looks far closer to the second. Every major driver behind this growth — rising cancer incidence, FDA clearances crossing the 690-device mark, precision-medicine adoption — points to a field embedding AI into its clinical backbone rather than experimenting at the margins. What's...

The global market for AI in oncology was valued at approximately USD 2.80 billion in 2023 and is projected to experience substantial growth, expanding at a compound annual growth rate (CAGR) of 28.92% between 2024 and 2030. Several key factors contribute to this rapid market expansion, including the rising global prevalence of cancer, advancements in cancer diagnostic technologies, improvements in healthcare infrastructure, and an increasing demand for early and accurate cancer detection. One of the main drivers of market growth is the surge in initiatives by both public and private organizations that are heavily investing in research and development (R&D) to introduce new and innovative technologies in oncology. A prime example of this trend is the launch of Tempus+, a program announced by Tempus, a leader in precision medicine and artificial intelligence (AI) applications. Tempus+ utilizes real-world data to enhance collaborative precision oncology research, with a community of ...

AI In Oncology Market Size & Trends The global AI in oncology market size was estimated at USD 2.80 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 28.92% from 2024 to 2030. The growth of the market is attributed to increasing prevalence of cancer, technological advancement in cancer diagnostics & healthcare infrastructure, and an increasing demand for early and accurate diagnosis of cancer. The growing initiatives undertaken by public and private organizations to invest in research and development (R&D) for introduction of novel technologies are further anticipated to fuel the market growth. For instance, in October 2022, Tempus, a company specializing in precision medicine and AI, recently announced a program called Tempus+. This proprietary program utilizes real-world data to power collaborative precision oncology research. A community of researchers, including Baylor College of Medicine, Allegheny Health Network, Stanford Cancer Cen...

AI In Oncology Market Growth & Trends The global  AI in oncology market  size is expected to reach USD 19.17 billion by 2030, registering a CAGR of 28.92% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is anticipated to witness significant growth owing to increasing prevalence of cancer among the global population, propelling the need to develop technologically advanced products to diagnose, treat, and analyze cancer. For instance, the International Agency for Research on Cancer (IARC) expects over 20.7 million new cases in 2023. Moreover, AI enables early detection, crucial for lowering mortality, especially through efficient screening programs. Emerging markets are witnessing a rising prevalence of cancer due to various factors, including lifestyle changes & aging populations. The surge in cancer cases in these markets creates a demand for advanced technologies like AI in oncology to improve early detection, personalized treatm...